Fintel on MSN
BTIG Reiterates Insulet (PODD) Buy Recommendation
Fintel reports that on November 13, 2025, BTIG reiterated coverage of Insulet (NasdaqGS:PODD) with a Buy recommendation.
Fintel reports that on November 7, 2025, Canaccord Genuity maintained coverage of Insulet (NasdaqGS:PODD) with a Buy ...
Insulet (PODD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
5d
Insulet (PODD): Evaluating Valuation After Q3 2025 Results, Upgraded Guidance, and Omnipod Expansion
Insulet (PODD) delivered third-quarter 2025 results that surpassed analyst predictions for both revenue and earnings. This outcome was due to meaningful expansion in its Omnipod insulin delivery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback